Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has maintained a Buy rating on Arrowhead Pharma (NASDAQ:ARWR) with a consistent price target of $60. This reaffirmation of Arrowhead Pharma's stock rating and price target indicates a positive outlook on the company's future performance by Chardan Capital.
May 10, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital's reaffirmation of a Buy rating and a $60 price target on Arrowhead Pharma suggests a strong confidence in the company's future performance and potential for stock price appreciation.
Analyst ratings and price targets are significant indicators for investors, often influencing stock prices. The maintenance of a Buy rating and a $60 price target by Chardan Capital for Arrowhead Pharma indicates a strong belief in the company's value and growth prospects. This could lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100